Proteonomix, Inc. (PROT) Receives FDA Permission to Initiate Company-Sponsored Phase 1 Clinical Trial With UMK-121 in Patients With End-Stage Liver Disease
8/14/2012 9:47:29 AM
MOUNTAINSIDE, N.J.--(BUSINESS WIRE)--Proteonomix, Inc. (OTC/BB: PROT), a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that the U.S. Food and Drug Administration (FDA) has granted permission to the Company to initiate a Phase 1 clinical trial with its mobilization technology UMK-121. The Proteonomix-sponsored trial will evaluate UMK-121 in patients with end-stage liver disease (ESLD).
comments powered by